Header Logo

Gary E Raskob

TitlePres,Vc Sr & Provost
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentOffice of the Provost
AddressLIB 221
1105 N Stonewall Ave
Oklahoma City OK 73117
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    U50DD000899     (RASKOB, GARY E.)Apr 1, 2012 - Mar 31, 2015
    NIH
    ACTIVE SURVEILLANCE FOR VENOUS THROMBOEMBOLISM IN A RACIALLY DIVERSE POPULATION
    Role: Principal Investigator
    R49CE000788     (RASKOB, GARY E.)Aug 1, 2005 - Jul 31, 2007
    NIH
    OU Developmental Center for Injury Prevention Research
    Role: Principal Investigator
    S07RR018224     (RASKOB, GARY E.)Sep 1, 2002 - Aug 31, 2006
    NIH
    OU Human Research Protection Program, Year 2
    Role: Principal Investigator
    P50HL054502     (MCEVER, RODGER PAUL)Mar 1, 1996 - Jan 31, 2006
    NIH
    THROMBOSIS: ETIOLOGY, RISK FACTORS AND TREATMENT
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lanting VR, Takada T, Bosch FTM, Marshall A, Grosso MA, Young AM, Lee AYY, Di Nisio M, Raskob GE, Kamphuisen PW, B?ller HR, van Es N. Risk of Recurrent Venous Thromboembolism in Patients with Cancer: An Individual Patient Data Meta-analysis and Development of a Prediction Model. Thromb Haemost. 2024 Oct 16. PMID: 39299270.
      Citations:    Fields:    
    2. Patell R, Hsu C, Shi M, Grosso MA, Duggal A, Buller HR, Raskob G, Zwicker JI. Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer. Haematologica. 2023 Oct 19; 0. PMID: 37855029.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    3. Raskob GE. Anticoagulant Therapy for Mechanical Heart Valves - Unmet Need Persists. NEJM Evid. 2023 Jul; 2(7):EVIDe2300106. PMID: 38320170.
      Citations:    Fields:    Translation:Humans
    4. Wang TF, Khorana AA, Agnelli G, Bloomfield D, Bonaca MP, B?ller HR, Connors JM, Goto S, Jing ZC, Kakkar AK, Khder Y, Raskob GE, Soff GA, Verhamme P, Weitz JI, Carrier M. Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction. Oncologist. 2023 May 12. PMID: 37171998.
      Citations: 3     Fields:    Translation:Humans
    5. de Winter MA, B?ller HR, Carrier M, Cohen AT, Hansen JB, Kaasjager KAH, Kakkar AK, Middeldorp S, Raskob GE, S?rensen HT, Visseren FLJ, Wells PS, Dorresteijn JAN, Nijkeuter M, VTE-PREDICT study group. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. Eur Heart J. 2023 04 07; 44(14):1231-1244. PMID: 36648242; PMCID: PMC10079391.
      Citations: 9     Fields:    Translation:Humans
    6. de Winter MA, Uijl A, B?ller HR, Carrier M, Cohen AT, Hansen JB, Kaasjager KHAH, Kakkar AK, Middeldorp S, Raskob GE, S?rensen HT, Wells PS, Nijkeuter M, Dorresteijn JAN. Redefining clinical venous thromboembolism phenotypes: a?novel approach using latent class analysis. J Thromb Haemost. 2023 03; 21(3):573-585. PMID: 36696208.
      Citations:    Fields:    Translation:Humans
    7. Spyropoulos AC, Raskob GE, Spiro TE, Lu W, De Sanctis Y, Albanese J, Mebazaa A, Barnathan ES. Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study. TH Open. 2022 Oct; 6(4):e304-e308. PMID: 36299620; PMCID: PMC9546607.
      Citations:    
    8. Raskob GE, Ageno W, Albers G, Elliott CG, Halperin J, Maynard G, Steg PG, Weitz JI, Albanese J, Yuan Z, Levitan B, Lu W, Suh EY, Spiro T, Lipardi C, Barnathan ES, Spyropoulos AC. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. J Am Heart Assoc. 2022 10 18; 11(20):e026229. PMID: 36205248; PMCID: PMC9673674.
      Citations: 3     Fields:    Translation:Humans
    9. Raskob GE, Wendelboe AM, Campbell J, Ford L, Ding K, Bratzler DW, McCumber M, Adamski A, Abe K, Beckman MG, Reyes NL, Richardson LC. Cancer-associated venous thromboembolism: Incidence and features in a racially diverse population. J Thromb Haemost. 2022 10; 20(10):2366-2378. PMID: 35830203.
      Citations: 4     Fields:    Translation:Humans
    10. Spyropoulos AC, Goldin M, Ageno W, Albers GW, Elliott CG, Hiatt WR, Halperin JL, Maynard G, Steg PG, Weitz JI, Spiro TE, Lu W, Marsigliano J, Raskob GE, Barnathan ES. Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. TH Open. 2022 Jul; 6(3):e177-e183. PMID: 36046208; PMCID: PMC9273326.
      Citations: 1     
    11. Wendelboe A, Saber I, Dvorak J, Adamski A, Feland N, Reyes N, Abe K, Ortel T, Raskob G. Exploring the Applicability of Using Natural Language Processing to Support Nationwide Venous Thromboembolism Surveillance: Model Evaluation Study. JMIR Bioinform Biotech. 2022 May 08; 3(1). PMID: 37206160; PMCID: PMC10193259.
      Citations: 4     
    12. Spyropoulos AC, Raskob GE, Cohen AT, Ageno W, Weitz JI, Spiro TE, Lu W, Lipardi C, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard G, Steg PG, Sugarmann C, Barnathan ES. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 2022 05 10; 145(19):1471-1479. PMID: 35389229.
      Citations: 4     Fields:    Translation:Humans
    13. Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, Mahaffey KW, Notani RS, Roberts R, Segers A, Raskob GE. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 12 02; 385(23):2161-2172. PMID: 34780683.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    14. Raskob GE, Spyropoulos AC, Spiro TE, Lu W, Yuan Z, Levitan B, Suh E, Barnathan ES. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. J Am Heart Assoc. 2021 11 16; 10(22):e021579. PMID: 34755519.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    15. Weitz JI, Raskob GE, Yi BA. Abelacimab for Prevention of Venous Thromboembolism. Reply. N Engl J Med. 2021 11 04; 385(19):1822-1823. PMID: 34731547.
      Citations:    Fields:    Translation:Humans
    16. Khan F, Tritschler T, Kimpton M, Wells PS, Kearon C, Weitz JI, Büller HR, Raskob GE, Ageno W, Couturaud F, Prandoni P, Palareti G, Legnani C, Kyrle PA, Eichinger S, Eischer L, Becattini C, Agnelli G, Vedovati MC, Geersing GJ, Takada T, Cosmi B, Aujesky D, Marconi L, Palla A, Siragusa S, Bradbury CA, Parpia S, Mallick R, Lensing AWA, Gebel M, Grosso MA, Thavorn K, Hutton B, Le Gal G, Fergusson DA, Rodger MA. Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. Ann Intern Med. 2021 10; 174(10):1420-1429. PMID: 34516270.
      Citations: 27     Fields:    Translation:Humans
    17. Bosch FTM, Mulder FI, Huisman MV, Zwicker JI, Di Nisio M, Carrier M, Segers A, Verhamme P, Middeldorp S, Weitz JI, Grosso MA, Duggal A, Büller HR, Wang TF, Garcia D, Kamphuisen PW, Raskob GE, van Es N. Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. J Thromb Haemost. 2021 12; 19(12):3008-3017. PMID: 34455706.
      Citations: 7     Fields:    Translation:Humans
    18. Khan F, Tritschler T, Kimpton M, Wells PS, Kearon C, Weitz JI, Büller HR, Raskob GE, Ageno W, Couturaud F, Prandoni P, Palareti G, Legnani C, Kyrle PA, Eichinger S, Eischer L, Becattini C, Agnelli G, Vedovati MC, Geersing GJ, Takada T, Cosmi B, Aujesky D, Marconi L, Palla A, Siragusa S, Bradbury CA, Parpia S, Mallick R, Lensing AWA, Gebel M, Grosso MA, Shi M, Thavorn K, Hutton B, Le Gal G, Rodger M, Fergusson D. Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2021 11; 19(11):2801-2813. PMID: 34379859.
      Citations: 8     Fields:    Translation:Humans
    19. Ageno W, Lopes RD, Goldin M, Yusen RD, Albers GW, Elliott GC, Halperin JL, Hiatt WR, Maynard G, Steg PG, Weitz JI, Suh E, Lu W, Barnathan ES, Raskob GE, Spyropoulos AC. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. J Thromb Haemost. 2021 11; 19(11):2772-2780. PMID: 34314574.
      Citations: 3     Fields:    Translation:Humans
    20. Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Büller HR, Raskob GE, Weitz JI. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 08 12; 385(7):609-617. PMID: 34297496.
      Citations: 72     Fields:    Translation:Humans
    21. Raskob GE, Spyropoulos AC, Cohen AT, Weitz JI, Ageno W, De Sanctis Y, Lu W, Xu J, Albanese J, Sugarmann C, Weber T, Lipardi C, Spiro TE, Barnathan ES. Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. J Am Heart Assoc. 2021 02; 10(5):e019459. PMID: 33586478.
      Citations: 11     Fields:    Translation:Humans
    22. Wendelboe AM, Campbell J, Ding K, Bratzler DW, Beckman MG, Reyes NL, Raskob GE. Incidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma. Thromb Haemost. 2021 Jun; 121(6):816-825. PMID: 33423245.
      Citations: 20     Fields:    Translation:Humans
    23. Lipardi C, Elliott CG, Sugarmann CL, Haskell L, Spyropoulos AC, Raskob GE, Xu J, Lu W, Marsigliano J, Spiro T, Yuan Z, Wu S, Barnathan ES. Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. Clin Appl Thromb Hemost. 2021 Jan-Dec; 27:10760296211053316. PMID: 34719984.
      Citations: 1     Fields:    Translation:Humans
    24. O'Connell C, Escalante CP, Goldhaber SZ, McBane R, Connors JM, Raskob GE. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. Oncologist. 2021 01; 26(1):e8-e16. PMID: 33275319.
      Citations: 23     Fields:    Translation:Humans
    25. Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Lu W, Spiro TE, Barnathan ES, Raskob GE. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. J Am Coll Cardiol. 2020 06 30; 75(25):3140-3147. PMID: 32586587.
      Citations: 26     Fields:    Translation:Humans
    26. Spyropoulos AC, Ageno W, Cohen AT, Gibson CM, Goldhaber SZ, Raskob G. Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. Thromb Haemost. 2020 Jun; 120(6):924-936. PMID: 32492724.
      Citations: 8     Fields:    Translation:Humans
    27. Spyropoulos AC, Lipardi C, Xu J, Peluso C, Spiro TE, De Sanctis Y, Barnathan ES, Raskob GE. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. TH Open. 2020 Jan; 4(1):e59-e65. PMID: 32190813.
      Citations: 63     
    28. Mulder FI, van Es N, Kraaijpoel N, Di Nisio M, Carrier M, Duggal A, Gaddh M, Garcia D, Grosso MA, Kakkar AK, Mercuri MF, Middeldorp S, Royle G, Segers A, Shivakumar S, Verhamme P, Wang T, Weitz JI, Zhang G, Büller HR, Raskob G. Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19]. Thromb Res. 2020 07; 191:156-159. PMID: 32151398.
      Citations:    Fields:    
    29. Mulder FI, Di Nisio M, Ay C, Carrier M, Bosch FTM, Segers A, Kraaijpoel N, Grosso MA, Zhang G, Verhamme P, Wang TF, Weitz JI, Middeldorp S, Raskob G, Beenen LFM, Büller HR, van Es N. Clinical implications of incidental venous thromboembolism in cancer patients. Eur Respir J. 2020 02; 55(2). PMID: 31727694.
      Citations: 18     Fields:    Translation:Humans
    30. Weitz JI, Raskob GE, Spyropoulos AC, Spiro TE, De Sanctis Y, Xu J, Lu W, Suh E, Argenti D, Yang H, Albanese J, Lipardi C, Barnathan ES. Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thromb Haemost. 2020 Mar; 120(3):515-524. PMID: 31975354.
      Citations: 13     Fields:    Translation:Humans
    31. Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, Metzig C, Raskob GE. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 01 14; 323(2):130-139. PMID: 31935028.
      Citations: 78     Fields:    Translation:HumansCTClinical Trials
    32. Mulder FI, van Es N, Kraaijpoel N, Di Nisio M, Carrier M, Duggal A, Gaddh M, Garcia D, Grosso MA, Kakkar AK, Mercuri MF, Middeldorp S, Royle G, Segers A, Shivakumar S, Verhamme P, Wang T, Weitz JI, Zhang G, Büller HR, Raskob G. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. Thromb Res. 2020 01; 185:13-19. PMID: 31733403.
      Citations: 27     Fields:    Translation:Humans
    33. Chiasakul T, Evans CR, Spyropoulos AC, Raskob G, Crowther M, Cuker A. Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. Thromb Res. 2019 Dec; 184:58-61. PMID: 31707152.
      Citations: 12     Fields:    Translation:Humans
    34. Weitz JI, Segers A, Raskob G, Roberts RS, Francis C, Lassen MR, Fuji T, Swaim RM, Lee M, Peters G, DiBattiste PM, Tesfaye F, Strony J. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 12; 17(12):2081-2088. PMID: 31529590.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    35. Di Nisio M, van Es N, Carrier M, Wang TF, Garcia D, Segers A, Weitz J, Buller H, Raskob G. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019 11; 17(11):1866-1874. PMID: 31271705.
      Citations: 20     Fields:    Translation:Humans
    36. Cohen AT, Agnelli G, Buller HR, Gallus A, Raskob GE, Sanders P, Thompson J, Weitz JI. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar; 119(3):461-466. PMID: 30650446.
      Citations: 4     Fields:    Translation:Humans
    37. Spyropoulos AC, Lipardi C, Xu J, Lu W, Suh E, Yuan Z, Levitan B, Sugarmann C, De Sanctis Y, Spiro TE, Barnathan ES, Raskob GE. Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin Appl Thromb Hemost. 2019 Jan-Dec; 25:1076029619886022. PMID: 31746218.
      Citations: 31     Fields:    Translation:Humans
    38. De Caterina R, Ageno W, Agnelli G, Chan NC, Diener HC, Hylek E, Raskob GE, Siegal DM, Verheugt FWA, Lip GYH, Weitz JI. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38. PMID: 30597497.
      Citations: 9     Fields:    Translation:Humans
    39. Spyropoulos AC, Barnathan ES, Raskob GE. Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 12 06; 379(23):2280. PMID: 30575454.
      Citations:    Fields:    Translation:Humans
    40. Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20; 379(12):1118-1127. PMID: 30145946.
      Citations: 109     Fields:    Translation:Humans
    41. Ten Cate H, Lensing AWA, Weitz JI, Middeldorp S, Beyer-Westendorf J, Kubitza D, Brighton T, Raskob GE, Mismetti P, Prandoni P, Gebel M, Prins MH. The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. Thromb Res. 2018 10; 170:75-83. PMID: 30121419.
      Citations: 2     Fields:    Translation:Humans
    42. Kraaijpoel N, Di Nisio M, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, Garcia D, Grosso M, Kakkar AK, Mercuri MF, Middeldorp S, Hernandez CR, Santamaria A, Schwocho L, Segers A, Verhamme P, Wang TF, Weitz JI, Zhang G, Zwicker JI, Büller HR, Raskob GE. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018 Aug; 118(8):1439-1449. PMID: 30060256.
      Citations: 67     Fields:    Translation:Humans
    43. Raskob GE, Büller HR, Segers A. Edoxaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 07 05; 379(1):95-96. PMID: 29972743.
      Citations: 9     Fields:    Translation:Humans
    44. Kraaijpoel N, van Es N, Raskob GE, Büller HR, Carrier M, Zhang G, Lin M, Grosso MA, Di Nisio M. Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2018 Jul; 118(7):1270-1278. PMID: 29864787.
      Citations: 6     Fields:    Translation:Humans
    45. Brekelmans MPA, Büller HR, Mercuri MF, Ageno W, Chen CZ, Cohen AT, van Es N, Grosso MA, Medina AP, Raskob G, Segers A, Vanassche T, Verhamme P, Wells PS, Zhang G, Weitz JI. Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. TH Open. 2018 Jan; 2(1):e1-e7. PMID: 31249922.
      Citations: 2     
    46. Kraaijpoel N, van Es N, Bleker SM, Brekelmans MPA, Eerenberg ES, Middeldorp S, Cohen AT, Raskob GE, Büller HR. Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. Thromb Haemost. 2018 01; 118(1):174-181. PMID: 29304537.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    47. Vanassche T, Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MPA, Chen CZ, Cohen AT, Grosso MA, Medina AP, Mercuri MF, Winters SM, Zhang G, Weitz JI, Raskob GE, Büller HR. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res. 2018 02; 162:7-14. PMID: 29248859.
      Citations: 9     Fields:    Translation:Humans
    48. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15; 378(7):615-624. PMID: 29231094.
      Citations: 519     Fields:    Translation:Humans
    49. Medina A, Raskob G, Ageno W, Cohen AT, Brekelmans MPA, Chen CZ, Grosso MA, Mercuri MF, Segers A, Verhamme P, Vanassche T, Wells PS, Lin M, Winters SM, Weitz JI, Büller HR. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2017 12; 117(12):2406-2414. PMID: 29212128.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    50. Bleker SM, Brekelmans MPA, Eerenberg ES, Cohen AT, Middeldorp S, Raskob G, Büller HR. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. Thromb Haemost. 2017 Oct; 117(10):1944-1951. PMID: 30151820.
      Citations: 7     Fields:    Translation:Humans
    51. Wendelboe AM, Raskob GE, Angchaisuksiri P, Blanco AN, Büller H, Ddungu H, Dvorak JD, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, McLintock C, Urano T, Weitz JI. Global public awareness about atrial fibrillation. Res Pract Thromb Haemost. 2018 Jan; 2(1):49-57. PMID: 30046706.
      Citations: 9     
    52. Bleker SM, Brekelmans MPA, Eerenberg ES, Cohen AT, Middeldorp S, Raskob G, Büller HR. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis. Thromb Haemost. 2017 10 05; 117(10):1944-1951. PMID: 28816341.
      Citations: 6     Fields:    Translation:Humans
    53. Wendelboe AM, St Germain L, Krolak B, Reiser T, Raskob G. Impact of World Thrombosis Day campaign. Res Pract Thromb Haemost. 2017 Jul; 1(1):138-141. PMID: 30046683.
      Citations: 2     
    54. Spyropoulos AC, Raskob GE. New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017 08 30; 117(9):1662-1670. PMID: 28640324.
      Citations: 20     Fields:    Translation:Humans
    55. Blumenthal DS, Raskob G. The Value of Prevention Research Centers: Breaking New Ground in Prevention Research. Am J Prev Med. 2017 03; 52(3 Suppl 3):S214-S215. PMID: 28215366.
      Citations:    Fields:    Translation:HumansPHPublic Health
    56. Di Nisio M, Raskob G, Büller HR, Grosso MA, Zhang G, Winters SM, Cohen A. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost. 2017 04 03; 117(4):784-793. PMID: 28151543.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    57. Ageno W, Casella IB, Han CK, Raskob GE, Schellong S, Schulman S, Singer DE, Kimura K, Tang W, Desch M, Goldhaber SZ. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost. 2017 01 26; 117(2):415-421. PMID: 27853808.
      Citations: 4     Fields:    Translation:Humans
    58. Brekelmans MP, Ageno W, Beenen LF, Brenner B, Buller HR, Chen CZ, Cohen AT, Grosso MA, Meyer G, Raskob G, Segers A, Vanassche T, Verhamme P, Wells PS, Zhang G, Weitz JI. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 Sep; 3(9):e437-45. PMID: 27570090.
      Citations: 10     Fields:    Translation:Humans
    59. Bleker SM, Cohen AT, Büller HR, Agnelli G, Gallus AS, Raskob GE, Weitz JI, Curto M, Sisson M, Middeldorp S. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thromb Haemost. 2016 Nov 30; 116(6):1159-1164. PMID: 27583312.
      Citations: 7     Fields:    Translation:Humans
    60. Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MP, Cohen AT, Meyer G, Grosso MA, Raskob G, Weitz JI, Zhang G, Buller H. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost. 2016 Sep 27; 116(4):747-53. PMID: 27440518.
      Citations: 15     Fields:    Translation:Humans
    61. Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, Büller HR. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug; 3(8):e379-87. PMID: 27476789.
      Citations: 64     Fields:    Translation:Humans
    62. Key NS, Khorana AA, Mackman N, McCarty OJ, White GC, Francis CW, McCrae KR, Palumbo JS, Raskob GE, Chan AT, Sood AK. Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Res. 2016 07 01; 76(13):3671-5. PMID: 27527638.
      Citations: 14     Fields:    Translation:Humans
    63. Wells PS, Prins MH, Levitan B, Beyer-Westendorf J, Brighton TA, Bounameaux H, Cohen AT, Davidson BL, Prandoni P, Raskob GE, Yuan Z, Katz EG, Gebel M, Lensing AWA. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension. Chest. 2016 Nov; 150(5):1059-1068. PMID: 27262225.
      Citations: 11     Fields:    Translation:HumansPHPublic Health
    64. Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiologic Aspects. Circ Res. 2016 Apr 29; 118(9):1340-7. PMID: 27126645.
      Citations: 410     Fields:    Translation:Humans
    65. Aelion CM, Airhihenbuwa CO, Alemagno S, Amler RW, Arnett DK, Balas A, Bertozzi S, Blakely CH, Boerwinkle E, Brandt-Rauf P, Buekens PM, Chandler GT, Chang RW, Clark JE, Cleary PD, Curran JW, Curry SJ, Diez Roux AV, Dittus R, Ellerbeck EF, El-Mohandes A, Eriksen MP, Erwin PC, Evans G, Finnegan JR, Fried LP, Frumkin H, Galea S, Goff DC, Goldman LR, Guilarte TR, Rivera-Gutiérrez R, Halverson PK, Hand GA, Harris CM, Healton CG, Hennig N, Heymann J, Hunter D, Hwang W, Jones RM, Klag MJ, Klesges LM, Lahey T, Lawlor EF, Maddock J, Martin WJ, Mazzaschi AJ, Michael M, Mohammed SD, Nasca PC, Nash D, Ogunseitan OA, Perez RA, Perri M, Petersen DJ, Peterson DV, Philbert M, Pinto-Martin J, Raczynski JM, Raskob GE, Rimer BK, Rohrbach LA, Rudkin LL, Siminoff L, Szapocznik J, Thombs D, Torabi MR, Weiler RM, Wetle TF, Williams PL, Wykoff R, Ying J. The US Cancer Moonshot initiative. Lancet Oncol. 2016 05; 17(5):e178-80. PMID: 27301041.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    66. Liles NW, Page EE, Liles AL, Vesely SK, Raskob GE, George JN. Diversity and severity of adverse reactions to quinine: A systematic review. Am J Hematol. 2016 May; 91(5):461-6. PMID: 26822544.
      Citations: 19     Fields:    Translation:Humans
    67. Brekelmans MP, Bleker SM, Bauersachs R, Boda Z, Büller HR, Choi Y, Gallus A, Grosso MA, Middeldorp S, Oh D, Raskob G, Schwocho L, Cohen AT. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thromb Haemost. 2016 07 04; 116(1):155-61. PMID: 27010092.
      Citations: 6     Fields:    Translation:Humans
    68. Raskob G, Ageno W, Cohen AT, Brekelmans MP, Grosso MA, Segers A, Meyer G, Verhamme P, Wells PS, Lin M, Winters SM, Weitz JI, Büller HR. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 May; 3(5):e228-36. PMID: 27132697.
      Citations: 19     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    69. Raskob G, Wendelboe AM. Global public awareness of venous thromboembolism: reply. J Thromb Haemost. 2016 05; 14(5):1111-2. PMID: 26866426.
      Citations:    Fields:    Translation:Humans
    70. Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016 06 02; 115(6):1240-8. PMID: 26842902.
      Citations: 34     Fields:    Translation:Humans
    71. Raskob GE, Gallus AS, Sanders P, Thompson JR, Agnelli G, Buller HR, Cohen AT, Ramacciotti E, Weitz JI. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost. 2016 Apr; 115(4):809-16. PMID: 26661288.
      Citations: 6     Fields:    Translation:Humans
    72. Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2016 Jan; 137:3-10. PMID: 26654719.
      Citations: 140     Fields:    Translation:Humans
    73. Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, Raskob GE, Weitz JI, Yamabe T. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015 Dec; 13(12):2187-91. PMID: 26407753.
      Citations: 82     Fields:    Translation:Humans
    74. van Es N, Di Nisio M, Bleker SM, Segers A, Mercuri MF, Schwocho L, Kakkar A, Weitz JI, Beyer-Westendorf J, Boda Z, Carrier M, Chlumsky J, Décousus H, Garcia D, Gibbs H, Kamphuisen PW, Monreal M, Ockelford P, Pabinger I, Verhamme P, Grosso MA, Büller HR, Raskob GE. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost. 2015 Nov 25; 114(6):1268-76. PMID: 26271200.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    75. Wendelboe AM, McCumber M, Hylek EM, Buller H, Weitz JI, Raskob G. Global public awareness of venous thromboembolism. J Thromb Haemost. 2015 Aug; 13(8):1365-71. PMID: 26084415.
      Citations: 47     Fields:    Translation:Humans
    76. Wendelboe AM, Campbell J, McCumber M, Bratzler D, Ding K, Beckman M, Reyes N, Raskob G. The design and implementation of a new surveillance system for venous thromboembolism using combined active and passive methods. Am Heart J. 2015 Sep; 170(3):447-54.e18. PMID: 26385027.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    77. Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015 Jan 15; 372(3):232-40. PMID: 25482425.
      Citations: 218     Fields:    Translation:HumansCTClinical Trials
    78. Rosendaal FR, Raskob GE. On World Thrombosis Day. Lancet. 2014 Nov 08; 384(9955):1653-4. PMID: 25319500.
      Citations: 4     Fields:    Translation:Humans
    79. Rosendaal FR, Raskob GE. On World Thrombosis Day. Lancet. 2014 Nov 08; 384(9955):1653-4. PMID: 25473673.
      Citations:    Fields:    Translation:Humans
    80. Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2363-71. PMID: 25304324.
      Citations: 304     Fields:    Translation:Humans
    81. Raskob GE, Angchaisuksiri P, Blanco AN, Büller H, Gallus A, Hunt BJ, Hylek EM, Kakkar TL, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost. 2014 Oct; 40(7):724-35. PMID: 25302681.
      Citations: 50     Fields:    
    82. Raskob GE. Oral anticoagulants: new and improved. Blood. 2014 Sep 18; 124(12):1851-2. PMID: 25606628.
      Citations:    Fields:    Translation:Humans
    83. Buller HR, Halperin J, Hankey GJ, Pillion G, Prins MH, Raskob GE. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost. 2014 Jun; 12(6):824-30. PMID: 24597472.
      Citations: 5     Fields:    Translation:Humans
    84. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013 Sep 20; 11(1):21. PMID: 24053656.
      Citations: 160     
    85. Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10; 369(15):1406-15. PMID: 23991658.
      Citations: 553     Fields:    Translation:Humans
    86. Raskob GE. Importance of subsegmental pulmonary embolism. Blood. 2013 Aug 15; 122(7):1094-5. PMID: 23950170.
      Citations: 4     Fields:    Translation:Humans
    87. Raskob G, Büller H, Prins M, Segers A, Shi M, Schwocho L, van Kranen R, Mercuri M. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost. 2013 Jul; 11(7):1287-94. PMID: 23574579.
      Citations: 29     Fields:    Translation:HumansPHPublic Health
    88. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29; 369(9):799-808. PMID: 23808982.
      Citations: 677     Fields:    Translation:Humans
    89. Nicolaides AN, Fareed J, Kakkar AK, Comerota AJ, Goldhaber SZ, Hull R, Myers K, Samama M, Fletcher J, Kalodiki E, Bergqvist D, Bonnar J, Caprini JA, Carter C, Conard J, Eklof B, Elalamy I, Gerotziafas G, Geroulakos G, Giannoukas A, Greer I, Griffin M, Kakkos S, Lassen MR, Lowe GD, Markel A, Prandoni P, Raskob G, Spyropoulos AC, Turpie AG, Walenga JM, Warwick D. Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol. 2013 Apr; 32(2):111-260. PMID: 24402349.
      Citations: 58     Fields:    Translation:Humans
    90. Pineo GF, Gallus AS, Raskob GE, Chen D, Ramirez LM, Ramacciotti E, Lassen MR, Wang L. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013 Mar; 11(3):444-51. PMID: 23279103.
      Citations: 13     Fields:    Translation:Humans
    91. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 02 21; 368(8):699-708. PMID: 23216615.
      Citations: 338     Fields:    Translation:Humans
    92. Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 04 05; 366(14):1287-97. PMID: 22449293.
      Citations: 659     Fields:    Translation:Humans
    93. Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, Lassen MR. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012 Feb; 94(2):257-64. PMID: 22323697.
      Citations: 32     Fields:    Translation:Humans
    94. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, Bonnet D, Schulze-Neick I, Barst RJ. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012 Feb 11; 379(9815):537-46. PMID: 22240409.
      Citations: 143     Fields:    Translation:Humans
    95. Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012 Jan 14; 379(9811):123-9. PMID: 22130488.
      Citations: 17     Fields:    Translation:Humans
    96. Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, Hirsh J, Kearon C. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011 May 24; 342:d3036. PMID: 21610040.
      Citations: 89     Fields:    Translation:Humans
    97. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23; 363(26):2487-98. PMID: 21175312.
      Citations: 204     Fields:    Translation:Humans
    98. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23; 363(26):2499-510. PMID: 21128814.
      Citations: 869     Fields:    Translation:Humans
    99. Weitz JI, Cao C, Eriksson BI, Fisher W, Kupfer S, Raskob G, Spaeder J, Turpie AG. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec; 104(6):1150-7. PMID: 20886185.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    100. Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Sep; 104(3):642-9. PMID: 20589317.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    101. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, Turner M, McGoon MD. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011 Jan; 139(1):128-37. PMID: 20558556.
      Citations: 145     Fields:    Translation:HumansCTClinical Trials
    102. van Doormaal FF, Cohen AT, Davidson BL, Decousus H, Gallus AS, Gent M, Piovella F, Prins MH, Raskob GE, Büller HR. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thromb Haemost. 2010 Jul; 104(1):86-91. PMID: 20508907.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    103. Raskob GE, Silverstein R, Bratzler DW, Heit JA, White RH. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med. 2010 Apr; 38(4 Suppl):S502-9. PMID: 20331950.
      Citations: 64     Fields:    Translation:HumansPHPublic Health
    104. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 06; 375(9717):807-15. PMID: 20206776.
      Citations: 203     Fields:    Translation:HumansCTClinical Trials
    105. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb; 137(2):376-87. PMID: 19837821.
      Citations: 454     Fields:    Translation:Humans
    106. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 06; 361(6):594-604. PMID: 19657123.
      Citations: 178     Fields:    Translation:Humans
    107. Hull RD, Pineo GF, Brant R, Liang J, Cook R, Solymoss S, Poon MC, Raskob G. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med. 2009 Aug; 122(8):762-769.e3. PMID: 19635277.
      Citations: 23     Fields:    Translation:Humans
    108. Prins MH, Guillemin I, Gilet H, Gabriel S, Essers B, Raskob G, Kahn SR. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes. 2009 Apr 07; 7:30. PMID: 19348685.
      Citations: 29     Fields:    Translation:Humans
    109. van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Büller HR. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr; 101(4):762-9. PMID: 19350123.
      Citations: 28     Fields:    Translation:HumansPHPublic Health
    110. McGoon MD, Krichman A, Farber HW, Barst RJ, Raskob GE, Liou TG, Miller DP, Feldkircher K, Giles S. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008 Aug; 83(8):923-31. PMID: 18674477.
      Citations: 51     Fields:    Translation:Humans
    111. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008 Sep 15; 112(6):2242-7. PMID: 18621928.
      Citations: 88     Fields:    Translation:HumansCTClinical Trials
    112. Stein PD, Sostman HD, Bounameaux H, Buller HR, Chenevert TL, Dalen JE, Goodman LR, Gottschalk A, Hull RD, Leeper KV, Pistolesi M, Raskob GE, Wells PS, Woodard PK. Challenges in the diagnosis of acute pulmonary embolism. Am J Med. 2008 Jul; 121(7):565-71. PMID: 18589050.
      Citations: 8     Fields:    Translation:Humans
    113. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):454S-545S. PMID: 18574272.
      Citations: 363     Fields:    Translation:Humans
    114. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan; 24(1):1-9. PMID: 18534438.
      Citations: 147     Fields:    Translation:Humans
    115. Rathbun SW, Whitsett TL, Raskob GE. Exclusion of first-episode deep-vein thrombosis after-hours using D-dimer. Blood Coagul Fibrinolysis. 2007 Dec; 18(8):795-800. PMID: 17982322.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    116. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 Dec 01; 25(34):5490-505. PMID: 17968019.
      Citations: 222     Fields:    Translation:Humans
    117. Kirkpatrick A, Rathbun S, Whitsett T, Raskob G. Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med. 2007 Oct; 120(10):901.e1-13. PMID: 17904462.
      Citations: 13     Fields:    Translation:Humans
    118. Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007 Sep 13; 357(11):1094-104. PMID: 17855670.
      Citations: 67     Fields:    Translation:Humans
    119. Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med. 2007 Sep 13; 357(11):1105-12. PMID: 17855671.
      Citations: 20     Fields:    Translation:HumansPHPublic Health
    120. Davidson BL, Büller HR, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob GE, Segers AE, Lensing AW. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost. 2007 Jun; 5(6):1191-4. PMID: 17403087.
      Citations: 15     Fields:    Translation:Humans
    121. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med. 2007 Jan; 120(1):72-82. PMID: 17208082.
      Citations: 18     Fields:    Translation:Humans
    122. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 Dec; 119(12):1062-72. PMID: 17145251.
      Citations: 152     Fields:    Translation:Humans
    123. Miller A, Campbell I, Fennerty T, Raskob GE, Büller HR. Duration of warfarin in pulmonary embolism. Chest. 2006 Jul; 130(1):299; author reply 299-300. PMID: 16840417.
      Citations:    Fields:    Translation:HumansPHPublic Health
    124. Hemenway D, Aglipay GS, Helsing KL, Raskob GE. Injury prevention and control research and training in accredited schools of public health: a CDC/ASPH assessment. Public Health Rep. 2006 May-Jun; 121(3):349-51. PMID: 16640161.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    125. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schünemann H. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest. 2006 Jan; 129(1):174-81. PMID: 16424429.
      Citations: 243     Fields:    Translation:Humans
    126. Rathbun SW, Whitsett TL, Raskob GE. Negative D-dimer result to exclude recurrent deep venous thrombosis: a management trial. Ann Intern Med. 2004 Dec 07; 141(11):839-45. PMID: 15583225.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    127. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):287S-310S. PMID: 15383476.
      Citations: 91     Fields:    Translation:Humans
    128. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):401S-428S. PMID: 15383479.
      Citations: 180     Fields:    Translation:HumansPHPublic Health
    129. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004 Jun 01; 140(11):867-73. PMID: 15172900.
      Citations: 97     Fields:    Translation:HumansCTClinical Trials
    130. Rathbun SW, Whitsett TL, Vesely SK, Raskob GE. Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest. 2004 Mar; 125(3):851-5. PMID: 15006941.
      Citations: 6     Fields:    Translation:Humans
    131. Sullivan SD, Davidson BL, Kahn SR, Muntz JE, Oster G, Raskob G. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics. 2004; 22(9):605-20. PMID: 15209529.
      Citations: 5     Fields:    Translation:Humans
    132. Henderson JN, Henderson LC, Raskob GE, Boatright DT. Chemical (VX) terrorist threat: public knowledge, attitudes, and responses. Biosecur Bioterror. 2004; 2(3):224-8. PMID: 15588061.
      Citations: 3     Fields:    Translation:Humans
    133. Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003 Dec; 124(6 Suppl):379S-385S. PMID: 14668421.
      Citations: 27     Fields:    Translation:Humans
    134. Davidson BL, Sullivan SD, Kahn SR, Borris L, Bossuyt P, Raskob G. The economics of venous thromboembolism prophylaxis: a primer for clinicians. Chest. 2003 Dec; 124(6 Suppl):393S-396S. PMID: 14668423.
      Citations: 1     Fields:    Translation:Humans
    135. George JN, Raskob GE, Vesely SK, Moore D, Lyons RM, Cobos E, Towell BL, Klug P, Guthrie TH. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol. 2003 Nov; 74(3):161-9. PMID: 14587042.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    136. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003 Oct 30; 349(18):1695-702. PMID: 14585937.
      Citations: 131     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    137. Blevins S, Edwards S, Raskob G. Helical computed tomography and magnet resonance imaging: diagnosis of pulmonary embolism in symptomatic patients. Curr Opin Hematol. 2003 Sep; 10(5):345-50. PMID: 12913788.
      Citations:    Fields:    Translation:Humans
    138. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003 Jul 01; 102(1):60-8. PMID: 12637323.
      Citations: 143     Fields:    Translation:Humans
    139. Sullivan SD, Kahn SR, Davidson BL, Borris L, Bossuyt P, Raskob G. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics. 2003; 21(7):477-96. PMID: 12696988.
      Citations: 14     Fields:    Translation:Humans
    140. Mustafa BO, Rathbun SW, Whitsett TL, Raskob GE. Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review. Arch Intern Med. 2002 Feb 25; 162(4):401-4. PMID: 11863471.
      Citations: 25     Fields:    Translation:Humans
    141. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, Butcher M, Brant RF, Ghali WA, Bergqvist D, Raskob GE. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001 Nov 20; 135(10):858-69. PMID: 11712876.
      Citations: 59     Fields:    Translation:Humans
    142. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, Ghali WA, Butcher MS, Brant RF, Bergqvist D, Hamulyák K, Francis CW, Marder VJ, Raskob GE. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 2001 Sep 10; 161(16):1952-60. PMID: 11525697.
      Citations: 25     Fields:    Translation:Humans
    143. Lee A, Agnelli G, Büller H, Ginsberg J, Heit J, Rote W, Vlasuk G, Costantini L, Julian J, Comp P, van Der Meer J, Piovella F, Raskob G, Gent M. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001 Jul 03; 104(1):74-8. PMID: 11435341.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    144. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 2001 Jan; 119(1 Suppl):108S-121S. PMID: 11157645.
      Citations: 85     Fields:    Translation:Humans
    145. Stein PD, Hull RD, Raskob GE. Withholding treatment in patients with acute pulmonary embolism who have a high risk of bleeding and negative serial noninvasive leg tests. Am J Med. 2000 Sep; 109(4):301-6. PMID: 10996581.
      Citations: 5     Fields:    Translation:Humans
    146. Birdwell BG, Raskob GE, Whitsett TL, Durica SS, Comp PC, George JN, Tytle TL, Owen WL, McKee PA. Predictive value of compression ultrasonography for deep vein thrombosis in symptomatic outpatients: clinical implications of the site of vein noncompressibility. Arch Intern Med. 2000 Feb 14; 160(3):309-13. PMID: 10668832.
      Citations: 6     Fields:    Translation:Humans
    147. Rathbun SW, Raskob GE, Whitsett TL. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med. 2000 Feb 01; 132(3):227-32. PMID: 10651604.
      Citations: 34     Fields:    Translation:Humans
    148. Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, Gottschalk A, Valentine KA, Mah AF. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med. 2000 Jan 24; 160(2):229-36. PMID: 10647762.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    149. Vesely S, Buchanan GR, Cohen A, Raskob G, George J. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists. J Pediatr Hematol Oncol. 2000 Jan-Feb; 22(1):55-61. PMID: 10695823.
      Citations: 8     Fields:    Translation:Humans
    150. Raskob GE, Hull RD. Diagnosis of pulmonary embolism. Curr Opin Hematol. 1999 Sep; 6(5):280-4. PMID: 10468141.
      Citations:    Fields:    Translation:Humans
    151. Rizvi MA, Shah SR, Raskob GE, George JN. Drug-induced thrombocytopenia. Curr Opin Hematol. 1999 Sep; 6(5):349-53. PMID: 10468152.
      Citations: 5     Fields:    Translation:Humans
    152. Tapson VF, Carroll BA, Davidson BL, Elliott CG, Fedullo PF, Hales CA, Hull RD, Hyers TM, Leeper KV, Morris TA, Moser KM, Raskob GE, Shure D, Sostman HD, Taylor Thompson B. The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. Am J Respir Crit Care Med. 1999 Sep; 160(3):1043-66. PMID: 10471639.
      Citations: 42     Fields:    Translation:Humans
    153. George JN, Woolf SH, Raskob GE. The evidence-based analysis of treatment for chronic myeloid leukemia: An introduction to its methods and clinical implications. Blood. 1999 Sep 01; 94(5):1515-6. PMID: 10477675.
      Citations:    Fields:    Translation:Humans
    154. Raskob GE. Heparin and low molecular weight heparin for treatment of acute pulmonary embolism. Curr Opin Pulm Med. 1999 Jul; 5(4):216-21. PMID: 10407690.
      Citations:    Fields:    Translation:Humans
    155. Hull RD, Brant RF, Pineo GF, Stein PD, Raskob GE, Valentine KA. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med. 1999 Jan 25; 159(2):137-41. PMID: 9927095.
      Citations: 10     Fields:    Translation:Humans
    156. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, Vondracek T. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998 Dec 01; 129(11):886-90. PMID: 9867731.
      Citations: 126     Fields:    Translation:Humans
    157. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 1998 Nov; 114(5 Suppl):511S-523S. PMID: 9822060.
      Citations: 19     Fields:    Translation:Humans
    158. Bratzler DW, Raskob GE, Murray CK, Bumpus LJ, Piatt DS. Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med. 1998 Sep 28; 158(17):1909-12. PMID: 9759687.
      Citations: 11     Fields:    Translation:Humans
    159. Hull RD, Pineo GF, Raskob GE. Hirudin versus heparin and low-molecular-weight heparin: and the winner is... J Lab Clin Med. 1998 Sep; 132(3):171-4. PMID: 9735921.
      Citations: 2     Fields:    Translation:HumansAnimals
    160. George JN, Raskob GE. Idiopathic thrombocytopenic purpura: diagnosis and management. Am J Med Sci. 1998 Aug; 316(2):87-93. PMID: 9704662.
      Citations: 4     Fields:    Translation:Humans
    161. Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Different effects of heparin in males and females. Clin Invest Med. 1998 Apr; 21(2):71-8. PMID: 9562927.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    162. George JN, Woolf SH, Raskob GE. Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. Ann Med. 1998 Feb; 30(1):38-44. PMID: 9556088.
      Citations: 5     Fields:    Translation:Humans
    163. George JN, Raskob GE. Idiopathic thrombocytopenic purpura: A concise summary of the pathophysiology and diagnosis in children and adults. Semin Hematol. 1998 Jan; 35(1 Suppl 1):5-8. PMID: 9523743.
      Citations: 3     Fields:    Translation:Humans
    164. Birdwell BG, Raskob GE, Whitsett TL, Durica SS, Comp PC, George JN, Tytle TL, McKee PA. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998 Jan 01; 128(1):1-7. PMID: 9424975.
      Citations: 35     Fields:    Translation:Humans
    165. Hull RD, Pineo GF, Raskob GE. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis. 1998; 28 Suppl 3:8-16. PMID: 10069757.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    166. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med. 1997 Dec 8-22; 157(22):2562-8. PMID: 9531224.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    167. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med. 1997 Nov 10; 157(20):2317-21. PMID: 9361572.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    168. Raskob GE, George JN. Thrombotic complications of antithrombotic therapy: a paradox with implications for clinical practice. Ann Intern Med. 1997 Nov 01; 127(9):839-41. PMID: 9382408.
      Citations: 5     Fields:    Translation:Humans
    169. George JN, Raskob GE. Clinical decisions in idiopathic thrombocytopenic purpura. Hosp Pract (1995). 1997 Sep 15; 32(9):159-60, 163-6, 169-70, passim. PMID: 9307602.
      Citations:    Fields:    Translation:Humans
    170. Raskob GE. Duration of anticoagulant treatment for venous thrombosis. Curr Opin Pulm Med. 1997 Jul; 3(4):286-90. PMID: 9262115.
      Citations:    Fields:    Translation:Humans
    171. Hull RD, Raskob GE, Rosenbloom D, Pineo GF, Lerner RG, Gafni A, Trowbridge AA, Elliott CG, Green D, Feinglass J. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):289-94. PMID: 9040295.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    172. Hull RD, Raskob GE, Pineo GF, Feldstein W, Rosenbloom D, Gafni A, Green D, Feinglass J, Trowbridge AA, Elliott CG. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):298-303. PMID: 9040296.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    173. Raskob GE, Durica SS, Owen WL, Comp PC. Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care. The Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1996 Nov 01; 78(9):1074-6. PMID: 8916497.
      Citations:    Fields:    Translation:Humans
    174. Raskob GE. Oral anticoagulant therapy. Curr Opin Hematol. 1996 Sep; 3(5):361-4. PMID: 9372102.
      Citations: 1     Fields:    Translation:Humans
    175. Henry JW, Stein PD, Gottschalk A, Raskob GE. Pulmonary embolism among patients with a nearly normal ventilation/perfusion lung scan. Chest. 1996 Aug; 110(2):395-8. PMID: 8697840.
      Citations: 2     Fields:    Translation:Humans
    176. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996 Jul 01; 88(1):3-40. PMID: 8704187.
      Citations: 236     Fields:    Translation:HumansPHPublic Health
    177. Raskob GE. Low molecular weight heparin for the prevention and treatment of venous thromboembolism. Curr Opin Pulm Med. 1996 Jul; 2(4):305-10. PMID: 9363157.
      Citations:    Fields:    Translation:Humans
    178. Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Aging and heparin-related bleeding. Arch Intern Med. 1996 Apr 22; 156(8):857-60. PMID: 8774204.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    179. Levine MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest. 1995 Oct; 108(4 Suppl):276S-290S. PMID: 7555182.
      Citations: 19     Fields:    Translation:Humans
    180. Hull RD, Raskob GE, Pineo GF, Brant RF. The low-probability lung scan. A need for change in nomenclature. Arch Intern Med. 1995 Sep 25; 155(17):1845-51. PMID: 7677550.
      Citations: 2     Fields:    Translation:Humans
    181. Raskob GE. Low molecular weight heparin, heparin, and warfarin. Curr Opin Hematol. 1995 Sep; 2(5):372-9. PMID: 9372022.
      Citations:    Fields:    Translation:Humans
    182. Raskob GE. Anticoagulants and thrombolysis in the treatment of pulmonary embolism. Curr Opin Pulm Med. 1995 Jul; 1(4):291-7. PMID: 9363067.
      Citations:    Fields:    Translation:Humans
    183. Hull RD, Feldstein W, Pineo GF, Raskob GE. Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost. 1995 Jul; 74(1):189-96. PMID: 8578456.
      Citations: 4     Fields:    Translation:Humans
    184. Raskob GE, Durica SS, Morrissey JH, Owen WL, Comp PC. Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood. 1995 Jun 01; 85(11):3034-9. PMID: 7756639.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    185. Raskob GE, Hull RD, Pineo GF. Impedance plethysmography for suspected deep-vein thrombosis. Arch Intern Med. 1995 Apr 10; 155(7):773, 776. PMID: 7695467.
      Citations:    Fields:    Translation:Humans
    186. George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1994 Nov 03; 331(18):1207-11. PMID: 7935660.
      Citations: 38     Fields:    Translation:Humans
    187. Goodman SG, Langer A, Durica SS, Raskob GE, Comp PC, Gray RJ, Hall JH, Kelley RP, Hua TA, Lee RJ, et al. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1994 Oct 01; 74(7):657-61. PMID: 7942522.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    188. Stein PD, Hull RD, Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management. Ann Intern Med. 1994 Sep 01; 121(5):313-7. PMID: 8042819.
      Citations: 9     Fields:    Translation:Humans
    189. Raskob GE, Durica SS. Treatment of venous thromboembolism. Curr Opin Hematol. 1994 Sep; 1(5):329-35. PMID: 9371301.
      Citations:    Fields:    Translation:Humans
    190. Raskob GE, Comp PC. Preventing systemic embolism in patients with abnormal ventricular function. Cardiol Clin. 1994 Aug; 12(3):477-85. PMID: 7805080.
      Citations:    Fields:    Translation:Humans
    191. Elliott CG, Hiltunen SJ, Suchyta M, Hull RD, Raskob GE, Pineo GF, Jensen RL, Yeates S, Kitterman N. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Arch Intern Med. 1994 May 09; 154(9):999-1004. PMID: 8179457.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    192. Hull RD, Raskob GE, Ginsberg JS, Panju AA, Brill-Edwards P, Coates G, Pineo GF. A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Intern Med. 1994 Feb 14; 154(3):289-97. PMID: 8297195.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    193. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993 Nov 04; 329(19):1370-6. PMID: 8413432.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    194. Raskob GE, Pineo GF, Hull RD. Impedance plethysmography and DVT diagnosis. Ann Intern Med. 1993 Aug 01; 119(3):247. PMID: 8323097.
      Citations:    Fields:    Translation:Humans
    195. Raskob GE. Long-term oral anticoagulant therapy for coronary artery disease. Haemostasis. 1993 Mar; 23 Suppl 1:32-41. PMID: 8495870.
      Citations:    Fields:    Translation:Humans
    196. Elliott CG, Suchyta M, Rose SC, Talbot S, Ford C, Raskob G, Hull R, Davidson B. Duplex ultrasonography for the detection of deep vein thrombi after total hip or knee arthroplasty. Angiology. 1993 Jan; 44(1):26-33. PMID: 8424582.
      Citations: 3     Fields:    Translation:Humans
    197. Levine MN, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of anticoagulant treatment. Chest. 1992 Oct; 102(4 Suppl):352S-363S. PMID: 1395820.
      Citations: 12     Fields:    Translation:Humans
    198. Hull RD, Raskob GE, Rosenbloom D, Lemaire J, Pineo GF, Baylis B, Ginsberg JS, Panju AA, Brill-Edwards P, Brant R. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. 1992 Aug; 152(8):1589-95. PMID: 1497392.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    199. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992 Apr 09; 326(15):975-82. PMID: 1545850.
      Citations: 84     Fields:    Translation:HumansCTClinical Trials
    200. Hull RD, Raskob GE. Venous thromboembolic disease. Curr Opin Cardiol. 1991 Oct; 6(5):750-6. PMID: 10150065.
      Citations: 1     Fields:    Translation:Humans
    201. Hull RD, Raskob GE. Low-probability lung scan findings: a need for change. Ann Intern Med. 1991 Jan 15; 114(2):142-3. PMID: 1984390.
      Citations: 6     Fields:    Translation:Humans
    202. Raskob GE, Hull RD. Diagnosis and management of pulmonary thromboembolism. Q J Med. 1990 Aug; 76(280):787-97. PMID: 2217683.
      Citations: 4     Fields:    Translation:Humans
    203. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martin GJ, Green D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990 May 03; 322(18):1260-4. PMID: 2183055.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    204. Hull RD, Raskob GE, Gent M, McLoughlin D, Julian D, Smith FC, Dale NI, Reed-Davis R, Lofthouse RN, Anderson C. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA. 1990 May 02; 263(17):2313-7. PMID: 2182917.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    205. Hull RD, Raskob GE, Carter CJ. Serial impedance plethysmography in pregnant patients with clinically suspected deep-vein thrombosis. Clinical validity of negative findings. Ann Intern Med. 1990 May 01; 112(9):663-7. PMID: 2334080.
      Citations: 9     Fields:    Translation:Humans
    206. Farrow L, Mungall D, Raskob G, Hull R. Predicting the daily prothrombin time response to warfarin. Ther Drug Monit. 1990 May; 12(3):246-9. PMID: 2349607.
      Citations: 2     Fields:    Translation:Humans
    207. Hull RD, Raskob GE, Coates G, Panju AA. Clinical validity of a normal perfusion lung scan in patients with suspected pulmonary embolism. Chest. 1990 Jan; 97(1):23-6. PMID: 2295242.
      Citations: 17     Fields:    Translation:Humans
    208. Hull RD, Raskob GE, Coates G, Panju AA, Gill GJ. A new noninvasive management strategy for patients with suspected pulmonary embolism. Arch Intern Med. 1989 Nov; 149(11):2549-55. PMID: 2818113.
      Citations: 16     Fields:    Translation:Humans
    209. Mungall D, Raskob G, Coleman R, Rosenbloom D, Ludden T, Hull R. Pharmacokinetics and dynamics of heparin in patients with proximal vein thrombosis. J Clin Pharmacol. 1989 Oct; 29(10):896-900. PMID: 2592581.
      Citations:    Fields:    Translation:Humans
    210. Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest. 1989 Feb; 95(2 Suppl):26S-36S. PMID: 2644101.
      Citations: 16     Fields:    Translation:Humans
    211. Fuller H, Raskob G, ter Keurs H, Hull R. The current status and future directions of impedance cardiography in ICU. Ann Biomed Eng. 1989; 17(5):483-94. PMID: 2610420.
      Citations:    Fields:    Translation:Humans
    212. Raskob GE, Carter CJ, Hull RD. Anticoagulant therapy for venous thromboembolism. Prog Hemost Thromb. 1989; 9:1-27. PMID: 2643814.
      Citations:    Fields:    Translation:Humans
    213. Raskob GE, Carter CJ, Hull RD. Heparin therapy for venous thrombosis and pulmonary embolism. Blood Rev. 1988 Dec; 2(4):251-8. PMID: 3061531.
      Citations: 3     Fields:    Translation:Humans
    214. Hull RD, Raskob GE, Carter CJ, Coates G, Gill GJ, Sackett DL, Hirsh J, Thompson M. Pulmonary embolism in outpatients with pleuritic chest pain. Arch Intern Med. 1988 Apr; 148(4):838-44. PMID: 3355304.
      Citations: 9     Fields:    Translation:Humans
    215. Hull RD, Raskob GE. Frequency of a normal lung scan observed in the urokinase-streptokinase pulmonary embolism trial. Invest Radiol. 1987 Apr; 22(4):357. PMID: 3583658.
      Citations:    Fields:    Translation:Humans
    216. Hirsh J, Hull RD, Raskob GE. Epidemiology and pathogenesis of venous thrombosis. J Am Coll Cardiol. 1986 Dec; 8(6 Suppl B):104B-113B. PMID: 3537063.
      Citations: 7     Fields:    Translation:Humans
    217. Hirsh J, Hull RD, Raskob GE. Clinical features and diagnosis of venous thrombosis. J Am Coll Cardiol. 1986 Dec; 8(6 Suppl B):114B-127B. PMID: 3537064.
      Citations: 12     Fields:    Translation:Humans
    218. Hirsh J, Hull RD, Raskob GE. Diagnosis of pulmonary embolism. J Am Coll Cardiol. 1986 Dec; 8(6 Suppl B):128B-136B. PMID: 3537065.
      Citations: 4     Fields:    Translation:Humans
    219. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986 Oct 30; 315(18):1109-14. PMID: 3531862.
      Citations: 90     Fields:    Translation:HumansCTClinical Trials
    220. Hull RD, Raskob GE, Hirsh J. The diagnosis of clinically suspected pulmonary embolism. Practical approaches. Chest. 1986 May; 89(5 Suppl):417S-425S. PMID: 3698720.
      Citations: 7     Fields:    Translation:Humans
    221. Hull RD, Raskob GE, Hirsh J. Prophylaxis of venous thromboembolism. An overview. Chest. 1986 May; 89(5 Suppl):374S-383S. PMID: 2421985.
      Citations: 11     Fields:    Translation:Humans
    222. Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest. 1986 Feb; 89(2 Suppl):16S-25S. PMID: 3510826.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    223. Hull RD, Raskob GE. Prophylaxis of venous thromboembolic disease following hip and knee surgery. J Bone Joint Surg Am. 1986 Jan; 68(1):146-50. PMID: 2416763.
      Citations: 14     Fields:    Translation:Humans
    224. Hull RD, Hirsh J, Carter CJ, Raskob GE, Gill GJ, Jay RM, Leclerc JR, David M, Coates G. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest. 1985 Dec; 88(6):819-28. PMID: 4064769.
      Citations: 37     Fields:    Translation:Humans
    225. Levine MN, Raskob G, Hirsh J. Risk of haemorrhage associated with long term anticoagulant therapy. Drugs. 1985 Nov; 30(5):444-60. PMID: 3905338.
      Citations: 5     Fields:    Translation:Humans
    226. Raskob GE, Lofthouse RN, Hull RD. Methodological guidelines for clinical trials evaluating new therapeutic approaches in bone and joint surgery. J Bone Joint Surg Am. 1985 Oct; 67(8):1294-7. PMID: 4055857.
      Citations: 2     Fields:    Translation:Humans
    227. Hull RD, Raskob GE, LeClerc JR, Jay RM, Hirsh J. The diagnosis of clinically suspected venous thrombosis. Clin Chest Med. 1984 Sep; 5(3):439-56. PMID: 6435945.
      Citations: 8     Fields:    Translation:Humans
    228. Hull RD, Raskob GE, Hirsh J, Sackett DL. A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. JAMA. 1984 Jul 13; 252(2):235-9. PMID: 6427492.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    229. Hull RD, Hirsh J, Carter CJ, Jay RM, Dodd PE, Ockelford PA, Coates G, Gill GJ, Turpie AG, Doyle DJ, Buller HR, Raskob GE. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med. 1983 Jun; 98(6):891-9. PMID: 6859705.
      Citations: 52     Fields:    Translation:Humans
    230. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982 Dec 30; 307(27):1676-81. PMID: 6755255.
      Citations: 85     Fields:    Translation:HumansCTClinical Trials
    231. Raskob G, Jay R, Hull R. Long-term anticoagulant therapy prevents recurrent venous thromboembolism. J R Soc Med. 1982 Apr; 75(4):289. PMID: 7069699.
      Citations:    Fields:    Translation:Humans
    Raskob's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (426)
    Explore
    _
    Co-Authors (7)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _